As medtech companies eye entry into the IVL space, Shockwave Medical is consolidating its position through innovation and ...

Shockwave Medical, Inc. SWAV, along with Genesis MedTech Group, received approval from China’s National Medical Products Administration for Intravascular Lithotripsy (“IVL”). The clearance paves the ...

Shockwave Medical, Inc. SWAV recently announced the full U.S. commercial availability of the Shockwave L6 Peripheral Intravascular Lithotripsy (IVL) Catheter. This follows the receipt of the FDA’s ...

Shockwave C2+ Catheter Expands Utility of IVL in Calcified Coronary Arteries Shockwave C2+ is commercially available for the treatment of de novo coronary artery disease in Europe and select other ...

SANTA CLARA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of ...

Next-generation intravascular lithotripsy (IVL) catheter resets physicians' expectations by addressing unmet needs in deliverability, lesion crossing and balloon repositioning Shockwave C2 Aero ...

Shockwave Medical is moving to get its Intravascular Lithotripsy (IVL) technology approved in Japan. The Santa Clara-based company said it has initiated the DISRUPT CAD IV study of IVL in heavily ...

Shockwave Medical, Inc. SWAV recently commercially launched the Shockwave M5+ peripheral intravascular lithotripsy (“IVL”) catheter. Commercial availability of the product in Europe and the United ...

Intravascular lithotripsy (IVL) has experienced strong uptake since Shockwave Medical became the first to market in the space ...

SANTA CLARA, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of ...